NASDAQ:ENTA

Enanta Pharmaceuticals - ENTA News Today

$39.60

-0.09 (-0.23%)

(As of 03/23/2023 12:00 AM ET)

Add

Compare

Today's Range: $38.86
▼
$40.45
50-Day Range: $39.60
▼
$54.59
52-Week Range: $37.59
▼
$79.50

Volume: 172,108 shs
Average Volume: 177,520 shs
Market Capitalization: $827.09 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $68.60

Institutional Ownership

Get Enanta Pharmaceuticals News Delivered to You Automatically

ENTA Media Mentions By Week

ENTA Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

ENTA
News Sentiment
▼
-0.18

0.35
▲
Average
Medical
News Sentiment

ENTA News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

ENTA Articles
This Week
▼
11

2
▲
ENTA Articles
Average Week

Source

Source	Headline
	Hennion & Walsh Asset Management Inc. Lowers Stock Holdings in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) marketbeat.com - March 23 at 5:18 AM
	Enanta Pharmaceuticals' (ENTA) "Sector Perform" Rating Reaffirmed at Royal Bank of Canada americanbankingnews.com - March 23 at 5:40 AM
	Expert Ratings for Enanta Pharma markets.businessinsider.com - March 22 at 7:53 PM
	Insider Selling: Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) VP Sells $618,966.25 in Stock americanbankingnews.com - March 20 at 5:06 AM
	Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Receives $68.60 Consensus Price Target from Brokerages americanbankingnews.com - March 20 at 2:02 AM
	Insider Selling: Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) CEO Sells $1,260,505.92 in Stock americanbankingnews.com - March 17 at 4:38 AM
	Enanta Pharmaceuticals to Present New Data for EDP-235, its 3CL Protease Inhibitor, in Development as an Oral, Once-Daily Treatment for COVID-19, at the 36th International Conference on Antiviral Research finance.yahoo.com - March 8 at 7:21 PM
	Enanta Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference finance.yahoo.com - March 7 at 10:08 AM
	Enanta Pharmaceuticals First Quarter 2023 Earnings: Beats Expectations finance.yahoo.com - February 9 at 3:17 PM
	Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Q1 2023 Earnings Call Transcript finance.yahoo.com - February 8 at 6:48 PM
	These Analysts Just Made A Huge Downgrade To Their Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) EPS Forecasts finance.yahoo.com - February 8 at 1:47 PM
	Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2022 with Webcast and Conference Call Today at 4:30 p.m. ET finance.yahoo.com - February 7 at 5:16 PM
	Enanta Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference finance.yahoo.com - February 7 at 7:15 AM
	Enanta Pharmaceuticals to Host Conference Call on February 7 at 4:30 p.m. ET to Discuss its Financial Results for Its Fiscal First Quarter Ended December 31, 2022 finance.yahoo.com - January 31 at 8:33 AM
	Enanta Pharmaceuticals (ENTA) Shares Cross Above 200 DMA nasdaq.com - January 24 at 9:07 PM
	SVB Securities Keeps Their Hold Rating on Enanta Pharmaceuticals (ENTA) markets.businessinsider.com - January 16 at 10:05 AM
	Analysts Conflicted on These Healthcare Names: Roche Holding AG (OtherRHHVF), Enanta Pharmaceuticals (ENTA) and Day One Biopharmaceuticals (DAWN) markets.businessinsider.com - January 10 at 1:01 PM
	An Intrinsic Calculation For Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Suggests It's 49% Undervalued finance.yahoo.com - January 6 at 9:00 AM
	Enanta Pharmaceuticals to Provide Updates on its Research and Development Programs and 2023 Outlook at the 41st Annual J.P. Morgan Healthcare Conference finance.yahoo.com - January 6 at 9:00 AM
	Enanta Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference finance.yahoo.com - January 3 at 10:25 AM
	Enanta: Deep Losses In FY 2022 Look To Be Justified Given Macro Landscape seekingalpha.com - December 30 at 1:34 PM
	Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Q4 2022 Earnings Call Transcript finance.yahoo.com - December 25 at 1:44 PM
	Newsflash: Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Analysts Have Been Trimming Their Revenue Forecasts finance.yahoo.com - November 23 at 6:52 AM
	Enanta Pharmaceuticals to Participate in Two Investor Conferences in November finance.yahoo.com - November 22 at 10:36 AM
	Enanta Pharmaceuticals, Inc. (ENTA) Q4 2022 Earnings Call Transcript seekingalpha.com - November 21 at 9:14 PM
	Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2022 With Webcast and Conference Call Today at 4:30 p.m. ET finance.yahoo.com - November 21 at 4:13 PM
	Earnings Outlook For Enanta Pharmaceuticals benzinga.com - November 18 at 10:42 AM
	Enanta Pharmaceuticals to Host Conference Call on November 21 at 4:30 p.m. ET to Discuss its Financial Results for Its Fiscal Fourth Quarter and Full Year Ended September 30, 2022 finance.yahoo.com - November 14 at 10:53 AM
	Enanta Pharmaceuticals Initiates SPRINT, a Phase 2 Clinical Trial of EDP-235, its Oral, Direct-Acting Antiviral Protease Inhibitor Specifically Designed for the Treatment of COVID-19 finance.yahoo.com - November 9 at 7:22 AM
	Investors in Enanta Pharmaceuticals (NASDAQ:ENTA) have unfortunately lost 51% over the last year finance.yahoo.com - November 3 at 2:54 PM
	Enanta Pharmaceuticals Presents New Preclinical Data for EDP-235, its Oral, Direct-Acting Antiviral Protease Inhibitor Specifically Designed for the Treatment of COVID-19 at IDWeek™ 2022 finance.yahoo.com - October 19 at 9:56 AM
	Enanta Pharmaceuticals, Inc. (ENTA) finance.yahoo.com - October 17 at 5:31 PM
	Enanta Pharmaceuticals Doses First Subject in a Phase 1 Clinical Study of EDP-323, its Novel, Oral L-Protein Inhibitor in Development for the Treatment Respiratory Syncytial Virus finance.yahoo.com - October 17 at 9:22 AM
	Enanta Pharmaceuticals Initiates a Phase 2b Clinical Study of EDP-938 in High-Risk Adults with Respiratory Syncytial Virus finance.yahoo.com - October 3 at 7:53 AM
	Enanta Pharmaceuticals Presents Preclinical Data for its Respiratory Syncytial Virus (RSV) and Human Metapneumovirus (hMPV) Programs at the 12th International RSV Symposium finance.yahoo.com - September 29 at 11:14 AM
	Enanta Pharmaceuticals Announces New Preclinical Data for its Respiratory Virology Programs to be Presented at the 12th International RSV Symposium finance.yahoo.com - September 22 at 10:23 AM
	New Preclinical Data for EDP-235, Enanta’s Oral Coronavirus Protease Inhibitor Designed for the Treatment of COVID-19, to be Presented at IDWeek™ 2022 finance.yahoo.com - September 7 at 11:32 AM
	Enanta Pharmaceuticals to Participate in Two Investor Conferences in September finance.yahoo.com - September 1 at 7:31 AM
	Need To Know: Analysts Just Made A Substantial Cut To Their Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Estimates finance.yahoo.com - August 14 at 6:51 PM
	The Petri Dish: Cyteir puts a drug on pause, Alexion vet joins Watertown biotech finance.yahoo.com - August 11 at 5:49 PM
	Enanta Pharmaceuticals (NASDAQ:ENTA) Has Debt But No Earnings; Should You Worry? nasdaq.com - August 9 at 8:18 PM
	Enanta Pharmaceuticals (ENTA) Q3 2022 Earnings Call Transcript finance.yahoo.com - August 9 at 2:47 AM
	Enanta Pharmaceuticals, Inc. (ENTA) CEO Jay Luly on Q3 2022 Results - Earnings Call Transcript seekingalpha.com - August 8 at 9:41 PM
	Enanta Pharmaceuticals (ENTA) Reports Q3 Loss, Lags Revenue Estimates finance.yahoo.com - August 8 at 9:41 PM
	Enanta Pharmaceuticals Appoints Scott T. Rottinghaus, M.D., as Senior Vice President and Chief Medical Officer finance.yahoo.com - August 8 at 4:40 PM
	Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2022 With Webcast and Conference Call Today at 4:30 p.m. ET finance.yahoo.com - August 8 at 4:40 PM
	Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Receives Consensus Rating of "Moderate Buy" from Brokerages americanbankingnews.com - August 4 at 1:12 AM
	Bullish Two Hundred Day Moving Average Cross - ENTA nasdaq.com - August 3 at 8:24 PM
	What 13 Analyst Ratings Have To Say About Enanta Pharmaceuticals markets.businessinsider.com - August 1 at 7:10 PM
	Enanta Pharmaceuticals to Host Conference Call on August 8 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Third Quarter Ended June 30, 2022 finance.yahoo.com - August 1 at 8:07 AM
	Enanta Shares Rise On Positive Data From Initial-Stage Covid Study markets.businessinsider.com - July 29 at 3:31 PM

Get Enanta Pharmaceuticals News Delivered to You Automatically

This page (NASDAQ:ENTA) was last updated on 3/24/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Enanta Pharmaceuticals - ENTA News Today

ENTA Media Mentions By Week

ENTA Media Sentiment

ENTA News Coverage

About MarketBeat

Popular Tools

Financial Calendars

Terms & Info